. 2012 Nov 7;7(11):e48747. doi: 10.1371/journal.pone.0048747

Table 3. Drug resistance mutations in HAARV-treated and drug-naïve patients in Guangdong, China.

No.	Sex		Risk factors	Months post-HAART		Plasma HIV RNA copies/ml	CD4⁺ T cells/µl	Subtype (pol/env)	Drug resistance mutations			Treatment (susceptibility)
									NRTI	NNRTI	PI
Treated group, 11 of 101 cases with drug-resistance mutations (HIVdb program analysis)
457		M	Heterosexual		2.2	2.0×10⁴	77	CRF07_BC/CRF07_BC	M184V^***, ^†			TDF(S),3TC(H),EFV(S)
440^§		M	Heterosexual		20.7	1.3×10⁵	142	CRF01_AE/CRF01_AE	M184V^***, V75S^‡	K101Q^, Y181C^,†,G190A^**		AZT(S),3TC(H),EFV(H)
437^§		M	Heterosexual		35.4	<50	303	CRF01_AE/CRF01_AE	V75S^, M184V^**	K101Q^, Y181C ^, G190A^**		D4T(L),3TC(H),EFV(H)
182		M	Heterosexual		14.6	<50	307	CRF01_AE/B	M184V^***, ^†, N348I^‡	K103N^***		D4T(S),3TC(H),Kaletera(S)
398		M	Heterosexual		27.1	<50	290	CRF01_AE/CRF01_AE	M184MV^***, ^†			D4T(S),3TC(H),EFV(S)
211		M	Heterosexual		41.7	<50	316	CRF01_AE/CRF01_AE	A62V^#, K65R^, ^††Q151M(V75I)^*	K101E^, G190A^Y181C(V179F)^		AZT(I),3TC(I),EFV(H)
326		M	IDU		68.3	<50	223	CRF01_AE/B	T215Y(M41L,L210W,D67N)^***, K219R^#	K103N(K238T)^* G190A^*	L33F^‡	D4T(H),3TC(L),NVP(H)
40		M	Heterosexual		0.5	96	222	URF/CRF02_AG			L10V^‡, G73C^‡	D4T(S),3TC(S),NVP(S)
14		M	MSM		1	59	334	CRF01_AE/CRF01_AE	T215IT^#			AZT(L),3TC(S),NVP(S)
115		M	IDU		2	<50	39	CRF01_AE/CRF01_AE		V179D^*		D4T(S),3TC(S),NVP(PL)
540		F	Heterosexual		56.5	<50	239	CRF02_AG/CRF02_AG		V179E^*		AZT(S),3TC(S),NVP(PL)
UNTREATED group, 3 of 68 cases with SDRM (2009)
372		M	Unknown		None	1.1×10⁴	375	CRF01_AE/CRF01_AE	K70R, V75M, M184V, K219N	K101E, Y181C, G190A
512		F	Heterosexual		None	1.0×10³	451	B/B			M46I
373		F	Unknown		None	<50	352	B/B	M41L, T215E

, **,*** indicate the low-level, intermediate or high-level resistance to HAART drugs administered, respectively.

^‡

indicates the existence of drug-resistance mutations while no corresponding drugs were administered to the patient.

^†

indicates the reduced susceptibility to one HAART drug administered to the patient, while increase the susceptibility to the other HAART drugs simultaneously.

^††

indicates the hyper-susceptibility to AZT.

^§

HIV-1 of patients 440 and 437 presented in the same transmission chain as identified by the PhyML analysis.

# indicates the mutations occurring with other drug-resistance mutations, while their effect on susceptibility is uncertain.

M, Male; F, Female; IDUs, intravenous drug users; MSM, Men having sex with men; SDRM, surveillance drug resistance mutation; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non- nucleoside reverse transcriptase inhibitors; PI, protease inhibitors; TDF, tenofovir; 3TC, lamivudine; AZT, zidovudine; d4T, stavudine; DDI, didanosine; NVP, nevirapine; EFV, efavirenz; Kaletera, combination of lopinavir and ritonavir; S, susceptible; H, high-level resistance; I, intermediate resistance; L, low-level resistance; and PL, potential low-level resistance.